You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
譽衡藥業(002437.SZ)下修業績預吿:2020年度預盈3.8億元–4.2億元
格隆匯 01-29 18:17

格隆匯 1 月 29日丨譽衡藥業(002437.SZ)披露2020年度業績預吿修正公吿,修正前,預計2020年度歸屬於上市公司股東的淨利潤為盈利6.2億元~6.8億元,變動幅度為123.29%~125.55%。修正後,預計歸屬於上市公司股東的淨利潤3.8億元–4.2億元,上年同期虧損26.62億元。業績預吿修正的主要原因如下:

1、受公司全資子公司上海華拓醫藥科技發展有限公司重點產品注射用磷酸肌酸鈉進入國家重點監控藥品目錄的持續影響,上海華拓經營業績持續虧損,2020年12月底經初步估計和測算,公司預計計提上海華拓無形資產減值準備、存貨跌價準備等造成損失約8,473萬元人民幣。

2、根據大同經開區綜合管理部於2020年12月下發的《關於印發<大同經開區冬季徵收專項行動實施方案>的通知》,公司下屬公司山西普德藥業有限公司原有閒置廠房被納入政府徵收範圍。此外,根據大同經濟技術開發區管委會下發的《關於印發大同經開區土地房屋徵收安置補償方案的通知》,並結合目前公司與有關部門就拆遷事項的溝通及初步評估情況,公司預計計提固定資產減值準備約4,278萬元人民幣。最終可回收金額將以日後簽署的正式協議金額為準。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account